Pfizer pill becomes 1st US-authorized home COVID treatment

WASHINGTON (AP) — U.S. health regulators on Wednesday authorized the first pill against COVID-19, a Pfizer drug that Americans will be able to take at home to head off the worst effects of the virus. The long-awaited milestone comes as U.S. cases, hospitalizations and deaths are all rising and health officials warn of a tsunami of new infections from the omicron variant that could overwhelm hospitals. The drug, Paxlovid, is a faster way to treat early COVID-19 infections, though initial supplies
— Read on ca.finance.yahoo.com/news/pfizer-pill-becomes-1st-us-172119608.html

FDA authorizes Pfizer’s Covid treatment pill, the first oral antiviral drug cleared during the pandemic

The FDA granted emergency authorization to Pfizer’s Covid treatment pill, a major milestone that promises to revolutionize the fight against the virus.
— Read on www.cnbc.com/2021/12/22/fda-authorizes-pfizers-covid-treatment-pill-the-first-oral-antiviral-drug-cleared-during-the-pandemic.html

Pfizer will dominate US$20 billion COVID-pill market in 2022, analysis shows – BNN Bloomberg

Pfizer will dominate US$20 billion COVID-pill market in 2022, analysis shows – BNN Bloomberg
— Read on www.bnnbloomberg.ca/pfizer-will-dominate-us-20-billion-covid-pill-market-in-2022-analysis-shows-1.1696959

Covid: Pfizer CEO sees a return to ‘normal’ globally by the end of 2022

By the end of 2022, there should be enough Covid vaccine doses for most world leaders to successfully inoculate their populations, Pfizer’s Albert Bourla said.
— Read on www.cnbc.com/2021/06/16/covid-pfizer-ceo-sees-a-return-to-normal-globally-at-the-end-of-2022.html

U.S. to pay Pfizer, BioNTech $1.95 billion for 100 million COVID-19 vaccine doses – Reuters

The U.S. government will pay $1.95 billion to buy 100 million doses of a COVID-19 vaccine being developed by Pfizer Inc and German biotech BioNTech SE <22UAy.F> if it proves to be safe and effective, the companies said on Wednesday.
— Read on www.reuters.com/article/us-health-coronavirus-usa-pfizer/u-s-to-pay-pfizer-biontech-1-95-billion-for-100-million-covid-19-vaccine-doses-idUSKCN24N1I9